Cogstate Ltd · ASX:CGS

Cogstate — Shareholder Meeting (October 2023)

16 slides from Cogstate's shareholder meeting presentation, Oct 25, 2023

  1. Slide 1: 2023 Annual General Meeting Presentation

    ASX Announcement 25 October 2023 2023 Annual General Meeting Presentation Cogstate Limited (ASX.CGS) attaches its 2023 Annual General Meeting Presentation, being presented to shareholders at today’s meeting. For personal use only This announcement was authorised for release by the Board of Directors

  2. Slide 2: About Cogstate

    About Cogstate Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitiv

  3. Slide 3: Annual General Meeting

    For personal use only Annual General Meeting Wednesday 25 October 2023 Start time: 11am Australian Eastern Daylight Savings Time (AEDT) © 2023 Cogstate Ltd. All rights reserved.

  4. Slide 4: Disclaimer

    Disclaimer For personal use only This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordan

  5. Slide 5: Board of Directors

    Board of Directors For personal use only Martyn Myer Brad O’Connor Non-Executive Chairman Managing Director / CEO Member: Audit, Risk & Compliance Committee Chair: Remuneration & Nomination Committee Richard van den Broek Richard Mohs Non-Executive Director Non-Executive Director Member: Remuneratio

  6. Slide 6: Every seconds, someone in the world develops dementia

    For personal use only Every 3 seconds, someone in the world develops dementia The societal impacts of Alzheimer’s disease are devastating. However, research breakthroughs for slowing the disease are finally gaining momentum. Cogstate has supported 100+ Alzheimer’s disease trials and developed leading

  7. Slide 7: First Alzheimer's Disease Modifying Therapies

    First Alzheimer’s Disease Modifying Therapies For personal use only Alzheimer’s Investment Expected To Increase Eisai’s Leqembi received FDA approval 06-Jul-23 US reimbursement of monoclonal antibodies confirmed by CMS following full FDA approval of Leqembi, with requirement for monitoring of patien

  8. Slide 8: Alzheimer's Disease Commercial Opportunity

    Alzheimer’s Disease Commercial Opportunity For personal use only Financial Significance Earlier Treatment Benefits Over FY22 & FY23: Timely diagnosis = better health outcomes 24% of the number of sales opportunities Cogstate tests are sensitive to earliest signs 70% of the value of sales contracts B

  9. Slide 9: First Approval For Rare Genetic Neurological Disease

    First Approval For Rare Genetic Neurological Disease For personal use only Rare Disease Investment Increasing Acadia’s Daybue received FDA approval 10-Mar-23 • First and only treatment for Rett syndrome • First approval of a treatment for a rare genetic neurological disease Dr Pam Ventola, VP Scienc

  10. Slide 10: Corporate Matters

    Corporate Matters For personal use only • Dec-2022: Discussion with 3rd party in relation to potential control transaction • Discussions remained non-binding and incomplete • Feb-2023: determined that the potential transaction would not proceed • Positive nature of discussions reflect long-term stra

  11. Slide 11: Corporate Matters: Share Buyback

    Corporate Matters For personal use only Share Buyback • Reflects cash position + Board view of strategic value • Buyback will be re-initiated following this meeting • Cash balance at 30-Sep-23: US$27.3m (US$28.7m at 30-Jun-23) Ø A$2.2m (approx. US$1.4m) used to acquire shares during the quarter Shar

  12. Slide 12: FY23 Financial Results

    FY23 Financial Results US$ Million 1H23 2H23 FY23 FY22 YTY% Revenue decline driven by delays associated with specific issues for a small For personal use only number of trials together with a low second Revenue 19.5 20.9 40.5 45.0 (10%) half new contract sales Decline in contribution margin, driven

  13. Slide 13: Clinical Trials Sales Contracts

    Clinical Trials Sales Contracts For personal use only 90 1Q24 sales contracts 80 • Solid start to FY24 70 • $9m contracts executed 60 • $8m net; after $1m of negative reconciliations during the quarter US$ Millions 50 • Alzheimer’s 72% of gross sales contracts 40 • Incl. Ph2 trial in pre-symptomatic

  14. Slide 14: Growth expectations

    Growth expectations For personal use only Clinical Trials Sales Pipeline • Substantial increase in proposal deliverables Ø 1Q24: 109 deliverables by our proposals team vs 4Q23: 64 deliverables Ø Sales timeline is such that most of that increase will impact Q2 or Q3 sales contracts • Value of sales o

  15. Slide 15: Momentum Returning

    For personal use only Momentum Returning Uniquely Positioned Existing Alzheimer’s customers planning new trials (most with CY 2024 start date) Leveraging successful Alzheimer’s trials to grow customer base Launch of Alzheimer’s therapies creates long-awaited opportunity in healthcare Cogstate techno

  16. Slide 16: For personal use only

    For personal use only

Cogstate — Shareholder Meeting (October 2023) on 6ix